臨床外科76巻2号

2021年02月発行

特集 外科医のための—悪性腫瘍補助療法のすべて 各論

直腸癌の術前術後補助療法

著者： 財津瑛子¹ 小西毅¹ 秋吉高志¹ 福長洋介¹

所属機関： ¹がん研究会有明病院消化器センター大腸外科

ページ範囲：P.185 - P.193

【ポイント】
◆下部直腸癌は再発率が高く，補助療法による局所再発および遠隔転移の制御は重要である．
◆術前（化学）放射線療法は局所再発を低減するが，遠隔転移の制御には寄与せず，術後補助化学療法のコンプライアンスが下がることが多い．
◆治癒切除可能な局所進行直腸癌の局所制御・予後改善を目的に，（化学）放射線療法と全身化学療法を術前にすべて投与するtotal neoadjuvant therapy（TNT）が注目を集めている．

参考文献

1）van Gijn W, Marijnen CAM, Nagtegaal ID, et al；Dutch Colorectal Cancer Group：Preoperative Radiotherapy Combined With Total Mesorectal Excision for Resectable Rectal Cancer：12-year Follow-Up of the Multicentre, Randomised Controlled TME Trial. Lancet Oncol 12：575-582, 2011　doi：10.1016/S1470-2045（11）70097-3

2）Sauer R, Liersch T, Merkel S, et al：Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer：results of the German CAO/ARO/AIO-94 randomized phase Ⅲ trial after a median follow-up of 11 years. J Clin Oncol 30：1926-1933, 2012　doi：10.1200/JCO.2011.40.1836

3）Gérard J-P, Conroy T, Bonnetain F, et al：Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers：Results of FFCD 9203. J Clin Oncol 24：4620-4625, 2006　doi：10.1200/JCO.2006.06.7629

4）Ngan SY, Burmeister B, Fisher RJ, et al：Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer：Trans-Tasman Radiation Oncology Group Trial 01.04. J Clin Oncol 30：3827-3833, 2012　doi：10.1200/JCO.2012.42.9597

5）Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al：Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93：1215-1223, 2006　doi：10.1002/bjs.5506

6）Weiser MR, Beets-Tan R, Beets G：Management of complete response after chemoradiation in rectal cancer. Surg Oncol Clin N Am 23：113-125, 2014　doi：10.1016/j.soc.2013.09.012

7）Weiser MR, Quah H-M, Shia J, et al：Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. Ann Surg 249：236-242, 2009　doi：10.1097/SLA.0b013e318195e17c

8）Sauer R, Becker H, Hohenberger W, et al：Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351：1731-1740, 2004　doi：10.1056/NEJMoa040694

9）Ito M, Saito N, Sugito M, et al：Analysis of clinical factors associated with anal function after intersphincteric resection for very low rectal cancer. Dis Colon Rectum 52：64-70, 2009　doi：10.1007/DCR.0b013e31819739a0

10）Marijnen CA, Kapiteijn E, van de Velde CJ, et al：Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer：report of a multicenter randomized trial. J Clin Oncol 20：817-825, 2002　doi：10.1200/JCO.2002.20.3.817

11）Birgisson H, Påhlman L, Gunnarsson U, et al：Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 23：6126-6131, 2005　doi：10.1200/JCO.2005.02.543

12）Birgisson H, Påhlman L, Gunnarsson U, et al；Swedish Rectal Cancer Trial Group. Adverse effects of preoperative radiation therapy for rectal cancer：long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 23：8697-8705, 2005　doi：10.1200/JCO.2005.02.9017

13）Birgisson H, Påhlman L, Gunnarsson U, et al：Late adverse effects of radiation therapy for rectal cancer-a systematic overview. Acta Oncol 46：504-516, 2007　doi：10.1080/02841860701348670

14）McLachlan S-A, Fisher RJ, Zalcberg J, et al：The impact on health-related quality of life in the first 12 months：A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer（Trans-Tasman Radiation Oncology Group Trial 01.04）. Eur J Cancer 55：15-26, 2016　doi：10.1016/j.ejca.2015.10.060

15）Yeo S-G, Kim DY, Kim TH, et al：Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer：long-term outcomes and prognostic significance of pathologic nodal status（KROG 09-01）. Ann Surg 252：998-1004, 2010　doi：10.1097/SLA.0B013E3181F3F1B1

16）Garcia-Aguilar J, Chow OS, Smith DD, et al：Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer：a multicentre, phase 2 trial. Lancet Oncol 16：957-966, 2015　doi：10.1016/S1470-2045（15）00004-2

17）Habr-Gama A, Perez RO, Nadalin W, et al：Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy：long-term results. Ann Surg 240：711-717；discussion 717-718, 2004　doi：10.1097/01.sla.0000141194.27992.32

18）中西良太，小西　毅：直腸癌に対する究極の機能温存手術—watch and wait policyの展望．外科81：480-486，2019

19）中西良太，小西　毅：直腸癌術前化学放射線療法後のWatch and See policy．臨外74：999-1004，2019

20）Renehan AG, Malcomson L, Emsley R, et al：Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer（the OnCoRe project）：a propensity-score matched cohort analysis. Lancet Oncol 17：174-183, 2016　doi：10.1016/S1470-2045（15）00467-2

）, 2019

22）Glynne-Jones R, Wyrwicz L, Tiret E, et al：Rectal cancer：ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28：iv22-iv40, 2017

23）van der Valk MJM, Hilling DE, Bastiaannet E, et al：Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch ＆ amp；Wait Database（IWWD）：an international multicentre registry study. Lancet 391：2537-2545, 2018　doi：10.1016/S0140-6736（18）31078-X

24）Fujita S, Mizusawa J, Kanemitsu Y, et al：Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage Ⅱ/Ⅲ Lower Rectal Cancer（JCOG0212）：A Multicenter, Randomized Controlled, Noninferiority Trial. Ann Surg 266：201-207, 2017　doi：10.1097/SLA.0000000000002212

25）Ogura A, Konishi T, Cunningham C, et al；Lateral Node Study Consortium：Neoadjuvant（Chemo）radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes：Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer. J Clin Oncol 37：33-43, 2019　doi：10.1200/JCO.18.00032

26）Sakamoto J, Hamada C, Yoshida S, et al：An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur（UFT）in patients with curatively resected rectal cancer. Br J Cancer 96：1170-1177, 2007　doi：10.1038/sj.bjc.6603686

27）Oki E, Murata A, Yoshida K, et al：A randomized phase Ⅲ trial comparing S-1 versus UFT as adjuvant chemotherapy for stage Ⅱ/Ⅲ rectal cancer（JFMC35-C1：ACTS-RC）. Ann Oncol Off J Eur Soc Med Oncol 27：1266-1272, 2016　doi：10.1093/annonc/mdw162

28）Hong YS, Kim SY, Lee JS, et al：Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy（ADORE）：Long-Term Results of a Randomized Controlled Trial. J Clin Oncol 37：3111-3123, 2019　doi：10.1200/JCO.19.00016

29）Bosset J-F, Calais G, Mineur L, et al：Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer：long-term results of the EORTC 22921 randomised study. Lancet Oncol 15：184-190, 2014　doi：10.1016/S1470-2045（13）70599-0

30）Garcia-Aguilar J, Patil S, Kim JK, et al；on behalf of the OPRA Consortium：Preliminary results of the organ preservation of rectal adenocarcinoma（OPRA）trial. J Clin Oncol 38（15_suppl）：abstract 4008, 2020　doi：10.1200/JCO.2020.38.15_suppl.4008

31）Hospers G, Bahadoer RR, Dijkstra EA, et al：Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer：The randomized RAPIDO trial. J Clin Oncol 38（15_suppl）, 2020　DOI：10.1200/JCO.2020.38.15_suppl.4006

32）Akiyoshi T, Ueno M, Matsueda K, et al：Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging. Ann Surg Oncol 21：189-196, 2014　doi：10.1245/s10434-013-3216-y

33）Ogura A, Akiyoshi T, Nagasaki T, et al：Feasibility of Laparoscopic Total Mesorectal Excision with Extended Lateral Pelvic Lymph Node Dissection for Advanced Lower Rectal Cancer after Preoperative Chemoradiotherapy. World J Surg 41：868-875, 2017　doi：10.1007/s00268-016-3762-0

34）Akiyoshi T, Toda S, Tominaga T, et al：Prognostic impact of residual lateral lymph node metastasis after neoadjuvant（chemo）radiotherapy in patients with advanced low rectal cancer. BJS open 3：822-829, 2019　doi：10.1002/bjs5.50194

35）Konishi T, Shinozaki E, Murofushi K, et al：Phase Ⅱ Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer. Ann Surg Oncol 26（8）：2507-2513, 2019　doi：10.1245/s10434-019-07342-7

36）Allegra CJ, Yothers G, O'Connell MJ, et al：Bevacizumab in stage Ⅱ-Ⅲ colon cancer：5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol 31：359-364, 2013　doi：10.1200/JCO.2012.44.4711

37）de Gramont A, Van Cutsem E, Schmoll HJ, et al：Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer（AVANT）：A phase 3 randomised controlled trial. Lancet Oncol 13：1225-1233, 2012　doi：10.1016/S1470-2045（12）70509-0

38）Chino A, Konishi T, Ogura A, et al：Endoscopic criteria to evaluate tumor response of rectal cancer to neoadjuvant chemoradiotherapy using magnifying chromoendoscopy. Eur J Surg Oncol 44：1247-1253, 2018　doi：10.1016/j.ejso.2018.04.013